Briefing materials released before Wednesday's panel review indicate the regulator wants clearer data to assess Amgen's experimental melanoma treatment.
We know it's early days (the smartwatch been available for three days to be exact), but we'd like to know how it is going.
The Centers for Medicare and Medicaid Services last year published 4.45 million records about financial relationships between industry and HCPs.
More pharma companies hike drug prices post-acquisition; HCV linked to increased risk of cancer; a combined Teva-Mylan would control 25% of the US generic drug market
Fueled by breakthrough drugs that actually broke through, spending on pharma products surged an incredible 13.1% in 2014, a figure that stunned even the sunniest of optimists. But with some of the contributing factors looking like one-time-only events, pundits wonder if perhaps the gains have been overstated—and don't get them started on the threat posed by payers pushing back against drug prices. Look for profiles of the 2015 top 20 pharma firms tomorrow, listed in order based on total US sales in 2014, plus a wealth of tabulated data
The Healthcare Businesswoman's Association 2015 Honorable Mentor has elevated mentoring to a prominent place.
The drugmaker said its top-selling multiple-sclerosis drug Tecfidera's slowdown in sales is due to competition from Plegridy as well as new patient concerns about risks of a rare brain infection.
An AbbVie hep.-C drug nabbed priority review; Merck's hep.-C drug matches efficacy of Harvoni; Mylan increased its bid to buy Perrigo
The drugmaker touted new data for its doublet regimen at the International Liver Congress, but it will likely have to look to the margins to find an underserved patient population.
First-quarter sales fell 1% but the drugmaker expects 2015 to be a growth year.
The hepatitis-C drug is being sold under the name MyHep.
Novo Nordisk's Saxenda to cost $1,000 a month; Boehringer Ingelheim's drug receives priority review; AbbVie's hep.-C treatment Viekira Pak generates $231 million in first-quarter sales
Established products fueled at 12% jump in first-quarter sales.
A court sided with Actavis in one product-hopping lawsuit for acne drug Doryx.
Xalkori received the designation to treat a new subset of non-small cell lung cancer patients.
The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.